Patents Assigned to Immunotope, Inc.
  • Patent number: 10206990
    Abstract: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as pancreatic carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against pancreatic and other cancers.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: February 19, 2019
    Assignee: Immunotope, Inc.
    Inventor: Ramila Philip
  • Patent number: 9907842
    Abstract: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as lung carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against lung and other cancers.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: March 6, 2018
    Assignee: Immunotope, Inc.
    Inventor: Ramila Philip
  • Publication number: 20170173135
    Abstract: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as pancreatic carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against pancreatic and other cancers.
    Type: Application
    Filed: March 2, 2017
    Publication date: June 22, 2017
    Applicant: Immunotope, Inc.
    Inventor: Ramila Philip
  • Publication number: 20170119869
    Abstract: Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. Herein, we report novel, naturally processed and presented MHC class I restricted epitopes, a subset of which binds to and activates T cells in both an HLA-A2 and HLA-A24 restricted manner.
    Type: Application
    Filed: May 11, 2015
    Publication date: May 4, 2017
    Applicant: Immunotope, Inc.
    Inventor: Ramila Philip
  • Patent number: 9624284
    Abstract: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as pancreatic carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against pancreatic and other cancers.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: April 18, 2017
    Assignee: Immunotope, Inc.
    Inventor: Ramila Philip
  • Publication number: 20160361410
    Abstract: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of Hepatitis B virus (HBV) infection, and discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against HBV infection. The peptide and/or proteins of the invention may be used as a therapeutic drug to stimulate the immune system to recognize and eliminate HBV infection in infected cells or as a vaccine for the prevention of disease.
    Type: Application
    Filed: February 13, 2015
    Publication date: December 15, 2016
    Applicant: Immunotope, Inc.
    Inventor: Ramila Philip
  • Patent number: 9132178
    Abstract: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as lung carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against lung and other cancers.
    Type: Grant
    Filed: June 13, 2010
    Date of Patent: September 15, 2015
    Assignee: Immunotope, Inc.
    Inventor: Ramila Philip
  • Publication number: 20140105925
    Abstract: Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHR) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. The present invention incorporates immunoproteomics to uncover novel HLA-A2 specific epitopes derived from Dengue Virus (DV)-infected cells. These epitopes are conserved with epitope-specific CTLs cross-reacting against all four DV serotypes. These epitopes have potential as new informational and diagnostic tools to characterize T cell immunity in Dengue virus (DV) infection, and serves as a universal vaccine candidate complementary to current vaccines.
    Type: Application
    Filed: June 28, 2012
    Publication date: April 17, 2014
    Applicant: Immunotope, Inc.
    Inventor: Ramila Philip
  • Publication number: 20110142919
    Abstract: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as ovarian carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against cancer.
    Type: Application
    Filed: February 18, 2011
    Publication date: June 16, 2011
    Applicant: Immunotope, Inc.
    Inventors: Venky Ramakrishna, Mark M. Ross, Ramila Philip
  • Patent number: 7919467
    Abstract: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as ovarian carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against cancer.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: April 5, 2011
    Assignee: Immunotope, Inc.
    Inventors: Venky Ramakrishna, Mark M. Ross, Ramila Philip, Lorraine H. Keller
  • Publication number: 20080207497
    Abstract: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as ovarian carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against cancer.
    Type: Application
    Filed: June 23, 2006
    Publication date: August 28, 2008
    Applicant: Immunotope, Inc.
    Inventors: Venky Ramakrishna, Mark M. Ross, Ramila Philip, Lorraine H. Keller
  • Publication number: 20080107668
    Abstract: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as breast carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against breast or cancer.
    Type: Application
    Filed: August 29, 2007
    Publication date: May 8, 2008
    Applicant: Immunotope, Inc.
    Inventors: Ramila Philip, Lorraine Keller
  • Patent number: 7083789
    Abstract: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as ovarian carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against cancer.
    Type: Grant
    Filed: December 4, 2001
    Date of Patent: August 1, 2006
    Assignee: Immunotope, Inc.
    Inventors: Venky Ramakrishna, Mark M. Ross, Ramila Philip